COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review.

Published on May 20, 2021in Neuroimmunology and Neuroinflammation7.724
· DOI :10.1212/NXI.0000000000001001
Mahdi Barzegar6
Estimated H-index: 6
,
Omid Mirmosayyeb10
Estimated H-index: 10
+ 5 AuthorsAmir-Hadi Maghzi20
Estimated H-index: 20
Source
Abstract
OBJECTIVE We systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS). METHODS We searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, Google Scholar, and World Health Organization database from December 1, 2019, to December 18, 2020. Three conference abstract databases were also searched. We included any types of studies that reported characteristics of patients with MS with COVID-19. RESULTS From an initial 2,679 publications and 3,138 conference abstracts, 87 studies (67 published articles and 20 abstracts) consisting of 4,310 patients with suspected/confirmed COVID-19 with MS met the inclusion criteria. The female/male ratio was 2.53:1, the mean (SD) age was 44.91 (4.31) years, the mean disease duration was 12.46 (2.27), the mean Expanded Disability Status Scale score was 2.54 (0.81), the relapsing/progressive ratio was 4.75:1, and 32.9% of patients had at least 1 comorbidity. The most common symptoms were fever (68.8%), followed by cough (63.9%), fatigue/asthenia (51.2%), and shortness of breath (39.5%). In total, 837 of 4,043 patients with MS with suspected/confirmed COVID-19 (20.7%) required hospitalization, and 130 of 4,310 (3.0%) died of COVID-19. Among suspected/confirmed patients, the highest hospitalization and mortality rates were in patients with no disease-modifying therapies (42.9% and 8.4%), followed by B cell-depleting agents (29.2% and 2.5%). CONCLUSION Our study suggested that MS did not significantly increase the mortality rate from COVID-19. These data should be interpreted with caution as patients with MS are more likely female and younger compared with the general population where age and male sex seem to be risk factors for worse disease outcome.
References48
Newest
#1Sukanthi Kovvuru (University of Arkansas for Medical Sciences)H-Index: 3
#2Krishna Nalleballe (University of Arkansas for Medical Sciences)H-Index: 7
Last. Bhaskar Roy (Yale University)H-Index: 11
view all 12 authors...
Abstract Objective To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). Methods We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders ...
11 CitationsSource
#1Nikos Evangelou (University of Nottingham)H-Index: 37
#2Afagh Garjani (NUH: Nottingham University Hospitals NHS Trust)H-Index: 3
Last. Richard NicholasH-Index: 9
view all 19 authors...
In the early phases of the UK COVID-19 outbreak, in the absence of clear evidence about the risks for people with multiple sclerosis (pwMS) and those taking immunomodulatory disease-modifying therapies (DMT), we launched a community-based study as part of the UK MS Register (UKMSR). We intended to capture the picture of COVID-19 among pwMS and their risk of contracting the disease. Here, we report our findings from 17 March to 24 April 2020. The COVID-19 study (clinicaltrials.gov:NCT04354519) is...
23 CitationsSource
#1Farhan Chaudhry (WSU: Wayne State University)H-Index: 5
#2Helena Bulka (HFHS: Henry Ford Health System)H-Index: 2
Last. Mirela Cerghet (WSU: Wayne State University)H-Index: 11
view all 15 authors...
Multiple sclerosis (MS) patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, there is little data identifying clinical characteristics of MS associated with worse COVID-19 outcomes. Therefore, we conducted a multicenter prospective cohort study looking at the outcomes of 40 MS patients with confirmed COVID-19. Severity of COVID-19 infection was based on hospital course, where a mild course was def...
27 CitationsSource
6 CitationsSource
#1James D. Bowen (UW: University of Washington)H-Index: 63
#2Justine Brink (UW: University of Washington)H-Index: 1
Last. Pavle Repovic (UW: University of Washington)H-Index: 8
view all 7 authors...
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalization. Mortality is higher with cardiovascular disorders, diabetes, and older age.1
25 CitationsSource
#1Erica Parrotta (Children's Medical Center of Dallas)H-Index: 1
#2Ilya Kister (Children's Medical Center of Dallas)H-Index: 27
Last. Lana Zhovtis Ryerson (Children's Medical Center of Dallas)H-Index: 7
view all 15 authors...
Objective To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness. Methods From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records. Results We identified 76 patients (55 with relapsing MS, of ...
77 CitationsSource
#1Céline Louapre (French Institute of Health and Medical Research)H-Index: 18
#2Nicolas Collongues (French Institute of Health and Medical Research)H-Index: 28
Last. Covisep investigatorsH-Index: 1
view all 20 authors...
Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. Objective To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity. Design, Setting, and Participants The Cov...
178 CitationsSource
#1Daniel P Oran (Scripps Health)H-Index: 4
#2Eric J. Topol (Scripps Health)H-Index: 223
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly throughout the world since the first cases of coronavirus disease 2019 (COVID-19) were observed in December 2019 in Wuhan, China. It has been suspected that infected persons who remain asymptomatic play a significant role in the ongoing pandemic, but their relative number and effect have been uncertain. The authors sought to review and synthesize the available evidence on asymptomatic SARS-CoV-2 infection. Asymptomat...
1,220 CitationsSource
#2Amirreza AzimiH-Index: 20
Last. Abdorreza Naser Moghadasi (Tehran University of Medical Sciences)H-Index: 12
view all 5 authors...
Abstract Background COVID-19 is increasingly expanding all over the world. People who have an underlying disease or taking immunosuppressive drugs are generally more likely to be infected than the others. Multiple sclerosis (MS) patients may also be at risk of the disease and its complications depending on the medication they are taking. In this study, we evaluated a large population of patients with MS with different disease modifying drugs to show if any of them increases the risk. In addition...
28 CitationsSource
#1Kathryn Rimmer (Columbia University)H-Index: 3
#2R. S. Farber (Columbia University)H-Index: 3
Last. Claire S Riley (Columbia University)H-Index: 12
view all 13 authors...
We report a fatal case of COVID-19 in a 51-year-old African American woman with multiple sclerosis on natalizumab. She had multiple risk factors for severe COVID-19 disease including race, obesity,...
5 CitationsSource
Cited By9
Newest
#1Gianmarco Bellucci (Sapienza University of Rome)H-Index: 3
#2Virginia Rinaldi (Sapienza University of Rome)H-Index: 1
Last. Rosella Mechelli (OU: Open University)H-Index: 3
view all 12 authors...
Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host’s genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune syste...
Source
#1Luca ProsperiniH-Index: 31
#2Carla TortorellaH-Index: 30
Last. Claudio GasperiniH-Index: 56
view all 6 authors...
To estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population. We conducted a pooled analysis of cohort studies on COVID-19 in patients with MS published until July 31, 2021. We calculated the pooled crude death rate (CDR) and estimated the indirectly-adjusted age-standardized lethality ratio (SLR) to assess the risk of death from COVID-19 in patients with MS as compared to general population. Out of 520 articles, 18 fulfilled...
3 CitationsSource
#2Nora MöhnH-Index: 8
view all 10 authors...
A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. A...
Source
#1Mahsa Khayat-Khoei (Brigham and Women's Hospital)H-Index: 5
#2Shamik Bhattacharyya (Brigham and Women's Hospital)H-Index: 9
Last. Rohit Bakshi (Brigham and Women's Hospital)H-Index: 79
view all 9 authors...
The availability of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID-19) pandemic. Vaccine safety and efficacy has not been established in individuals with chronic autoimmune diseases such as multiple sclerosis (MS). Anecdotal reports suggest that the vaccines may be associated with brain, spinal cord, peripheral nervous system, and cardiac inflammation. Based on the high morbidity and unpre...
Source
Source
#1Mehmet Özkeskin (Ege University)H-Index: 2
#2Fatih Özden (Muğla University)H-Index: 2
Last. Nur Yüceyar (Ege University)H-Index: 16
view all 5 authors...
Abstract null null Purpose null The study was purposed to investigate the effect of COVID-19 disease on fatigue, sleep quality, physical activity, quality of life, and psychological status in people with MS. null null null Methods null A total of 104 people with MS, including 46 of them with COVID-19 disease history, were enrolled in the study. All patients were evaluated with the Expanded Disability Status Scale (EDSS), Fatigue Severity Scale (FSS), Pittsburgh Sleep Quality Index (PSQI), Intern...
Source
#1Itay Lotan (TAU: Tel Aviv University)H-Index: 8
#2Adi Wilf-Yarkoni (TAU: Tel Aviv University)H-Index: 1
Last. Mark A. Hellmann (TAU: Tel Aviv University)H-Index: 11
view all 6 authors...
Background and purpose null Although the COVID-19 vaccines are currently recommended for people with multiple sclerosis (MS), the fact that they were not specifically tested in people with MS raises uncertainty regarding their safety in this population. The purpose of this study was to report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients. null Methods null An anonymous survey was distributed to 425 MS patients. Participants were asked general demographic and d...
2 CitationsSource
Objectives: Olfactory dysfunction is a major comorbidity observed in patients with multiple sclerosis, yet different prevalence rates are reported for it. Therefore, we have designed this systematic review to estimate the pooled prevalence of olfactory dysfunction in patients with MS. To our knowledge, this is the first systematic review and meta-analysis on the prevalence of olfactory dysfunction in MS patients. Method: We searched PubMed, Scopus, EMBASE, Web of Science, ProQuest, and gray lite...
Source
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 6
#2bagherieh S (IUMS: Isfahan University of Medical Sciences)
Last. Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 9 authors...
Background: We conducted this systematic review to identify factors associated with coronavirus disease (COVID-19) susceptibility and outcomes among people with multiple sclerosis (MS). Methods: Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature including reference list and conference abstracts were searched from December 1, 2019, through April 12, 2021. We included cross-sectional, case-control, and cohort studies that reported risk factors of contracting COVID-1...
Source